Loongson Technology(SH:688047) Xin Lang Cai Jing·2025-09-16 06:22Group 1: Market Performance - The Sci-Tech Innovation Board Index (000680) has surged by 1.31%, with notable increases in constituent stocks such as Loongson Technology (688047) up by 15.86%, Weichuang Electric (688698) up by 11.32%, and Tonglian Precision (688210) up by 10.87% [1] - After a period of adjustment, the index is experiencing a strong rebound driven by multiple positive factors [1] Group 2: Policy and Corporate Actions - The "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" initiative for the Sci-Tech Innovation Board is progressing, with nearly 90% of companies disclosing their 2025 action plans by early September [1] - Over 70% of the 589 companies on the board have directed their initial fundraising towards R&D and production, with total investments exceeding 650 billion yuan [1] - There is a notable increase in companies' awareness of returning value to shareholders, with 79 companies announcing mid-term dividend plans totaling over 6.1 billion yuan since 2025 [1] Group 3: Fund Flow and Institutional Investment - Pension funds, referred to as the "national team," have increased their allocation to the Sci-Tech Innovation Board, appearing in the top ten shareholders of 21 stocks by the end of Q2, with a total market value of 3.456 billion yuan [2] - Continuous inflow of institutional funds is providing stability to the market and creating opportunities for excess returns in index-enhanced products [2] Group 4: Industry Trends - The core sectors of the Sci-Tech Innovation Board are driving growth, particularly in semiconductors, with companies like Cambrian receiving approval for a 3.985 billion yuan private placement focused on chip platform R&D [2] - Leading semiconductor firms, such as Huahong Semiconductor, reported a 18.3% year-on-year increase in sales revenue and a capacity utilization rate of 108.3%, indicating accelerated domestic substitution in the semiconductor industry [2] - In the biopharmaceutical sector, innovative drug companies on the board completed 14 overseas licensing transactions in the first half of the year, with potential total transaction amounts exceeding 12 billion USD, showcasing international recognition of domestic innovation [2]